|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM307262634 |
| 003 |
DE-627 |
| 005 |
20231225125200.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231225s2020 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2020.108377
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1024.xml
|
| 035 |
|
|
|a (DE-627)NLM307262634
|
| 035 |
|
|
|a (NLM)32135278
|
| 035 |
|
|
|a (PII)S1521-6616(20)30055-3
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Yang, Huaxia
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Immune-related adverse events of checkpoint inhibitors
|b Insights into immunological dysregulation
|
| 264 |
|
1 |
|c 2020
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 19.10.2020
|
| 500 |
|
|
|a Date Revised 19.10.2020
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2020 Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a Immune checkpoint inhibitors (ICIs) targeting against programmed cell death-1(PD-1) and cytotoxic T-lymphocyte antigen-4 (CTLA-4) have shown efficacy in cancer treatment. However, a spectrum of immune-related adverse events (irAEs) have raised concerns about their clinical application. IrAEs are distinct from traditional chemo- and radiotherapy-induced toxicities, as they are related in particular to the dysregulation of immune system and autoimmunity. The underlying pathogenesis of irAEs remains elusive. Understanding of the potential underlying mechanism is of great importance for the management of irAEs and the development of new ICIs with insignificant irAEs. In this review, we summarize the current evidence to provide insights into the biological basis of irAEs and provide a potential explanation for their pathogenesis, with focus on the relationship between checkpoint molecules and immune cell regulation
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
4 |
|a Review
|
| 650 |
|
4 |
|a Cancer
|
| 650 |
|
4 |
|a Immune checkpoint inhibitors
|
| 650 |
|
4 |
|a Immune-related adverse events
|
| 650 |
|
4 |
|a Pathogenesis
|
| 650 |
|
7 |
|a Antineoplastic Agents
|2 NLM
|
| 650 |
|
7 |
|a Immunologic Factors
|2 NLM
|
| 700 |
1 |
|
|a Yao, Zhuoran
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhou, Xiaoxiang
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhang, Wen
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhang, Xuan
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhang, Fengchun
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 213(2020) vom: 30. Apr., Seite 108377
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:213
|g year:2020
|g day:30
|g month:04
|g pages:108377
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2020.108377
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 213
|j 2020
|b 30
|c 04
|h 108377
|